ReShape Lifesciences Inc.
RSLS
$0.6355
$0.00050.08%
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Net Income | 72.98% | 74.09% | 73.21% | 75.36% | 60.61% |
Total Depreciation and Amortization | -96.37% | -94.03% | -93.22% | -92.85% | -69.81% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -101.03% | -96.76% | -97.44% | -107.43% | -74.78% |
Change in Net Operating Assets | 140.56% | 91.74% | -384.27% | -683.07% | -7,687.10% |
Cash from Operations | 64.25% | 56.29% | 28.66% | 22.56% | 22.97% |
Capital Expenditure | 100.00% | 100.00% | 72.52% | 67.18% | -2.52% |
Sale of Property, Plant, and Equipment | -100.00% | -100.00% | 10.00% | -15.38% | -15.38% |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | 100.00% | 100.00% | 97.03% | 89.13% | 97.11% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -60.68% | -60.69% | -44.69% | 461.47% | 425.24% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 200.00% | -- | -- | -- | -- |
Cash from Financing | -56.98% | -60.69% | -44.69% | 461.47% | 411.68% |
Foreign Exchange rate Adjustments | 123.08% | 122.73% | 86.36% | -100.00% | -166.67% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 84.97% | 48.90% | -3.56% | 103.20% | 79.63% |